Friday, 14 Jun 2019

You are here

Presenting Features of Early SLE

What clinical features best identify early systemic lupus erythematosus (SLE) patients from mimics?  A multicenter, multinational study aimed to evaluate manifestations at disease onset and to compare early SLE manifestations to those of diseases mimicking SLE.

Baseline, presenting data from academic lupus centers in Asia, Europe, North America, and South America on patients presenting for possible SLE with a symptom duration of <1 year. The diagnosis of SLE was based on the 1997 American College of Rheumatology (ACR) SLE classification criteria and the 2012 Systemic Lupus International Collaborating Clinics (SLICC) SLE classification criteria. 

A cohort comparison of 389 patients with early SLE and 227 patients with SLE‐mimics demonstrated the following features that distinguished SLE from other conditions.

 SLEMimicsp value
Unexplained Fever34.5%13.7%<0.001
Raynauds22.1%48.5%<0.001
Sicca Sx4.4%34.4%<0.001
Dysphagia0.3%6.2%<0.001
Fatigue28.3%37%0.024

While unexplained fever better identified early SLE, the presence of Raynauds, Sicca complex, dysphagia and fatigue were more apt to indication an SLE‐mimicking condition.

Lupus criteria features were affirmed as reliable distinguishing features, including malar rash (50% vs 6%), photosensitivity (32% vs 19%), oral ulcers (22% vs 5%), alopecia (31% vs 12%), pleuritis ( 22% vs 3%), etc.

Similarly, double‐stranded DNA and anti–β2‐glycoprotein I antibodies, positive Coombs’ test results, autoimmune hemolytic anemia, hypocomplementemia, and leukopenia were more common in early SLE than in SLE‐mimicking conditions.

. Fewer patients with early SLE were not identified as having early SLE with use of the SLICC criteria compared to the ACR criteria (16.5% versus 33.9%), but the ACR criteria demonstrated higher specificity than the SLICC criteria (91.6% versus 82.4%).

This cohort study affirms the clinical manifestations that help distinguish early SLE from SLE‐mimicking conditions. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Lupus Disease Control with Rituximab

Rituximab (Rituxan) may be an option for maintenance therapy in patients with difficult-to-treat systemic lupus erythematosus (SLE), European researchers reported.

2019 EULAR Guidelines on Antiphospholipid Syndrome Management

A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.

Lupus Outcomes Influenced by Race/Ethnicity

A lupus registry from San Francisco County analyzed racial/ethnic differences in lupus manifestations and found significant differences in SLE manifestations among racial/ethnic groups. Researchers found that Blacks, Asians/Pacific Islanders (API), and Hispanics are more likely to develop severe manifestations following a diagnosis of SLE. From their database, they identified 724 SLE patients, and identified specific features in different subgroups.

Risk Score Predicts Thrombosis Recurrence in APS

A combination risk score helped predict recurrent thrombosis -- particularly arterial -- among patients with antiphospholipid syndrome (APS), an international study found.

Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus

A Morbidity and Mortality Weekly Report on a registry of systemic lupus erythematosus (SLE) patients from two Georgia counties (Fulton and Dekalb) shows SLE mortality was 2-3 times higher compared to the general population, especially amongst blacks; notably deaths occurred sooner after diagnosis and at a mean age approximately 13 years younger.